

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5292191

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE	07/01/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	KM BIOLOGICS CO., LTD.
<b>Street Address:</b>	1-6-1 OKUBO, KITA-KU
<b>Internal Address:</b>	KUMAMOTO-SHI
<b>City:</b>	KUMAMOTO
<b>State/Country:</b>	JAPAN
<b>Postal Code:</b>	8608568
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	13640623
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(650)493-6811
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(650) 493-9300
<b>Email:</b>	jholland@wsgr.com
<b>Correspondent Name:</b>	WILSON SONSINI GOODRICH & ROSATI
<b>Address Line 1:</b>	650 PAGE MILL ROAD
<b>Address Line 4:</b>	PALO ALTO, CALIFORNIA 94304-1050
<b>ATTORNEY DOCKET NUMBER:</b>	37974-724.831
<b>NAME OF SUBMITTER:</b>	SHAN LIU
<b>SIGNATURE:</b>	/SHAN LIU/
<b>DATE SIGNED:</b>	12/19/2018
<b>Total Attachments: 1</b>	
source=Assignment_13640623#page1.tif	

**PATENT ASSIGNMENT**

WHEREAS, KM Biologics Co., Ltd., having a place of business at 1-6-1 Okubo, Kita-ku, Kumamoto-shi, Kumamoto 8608568, Japan (hereinafter "Assignee") acquired on July 1, 2018 from The Chemo-Sero-Therapeutic Research Institute, having a place of business at 4-7 Hanabata-cho, Chuou-ku, Kumamoto-shi, Kumamoto 8600806, Japan (hereinafter "Assignor"), all the right, title and interest that The Chemo-Sero-Therapeutic Research Institute holds in and to the inventions disclosed in the patents and patent applications listed below:

Title	Country/Region	Patent Application No.	Patent No.
Methods and Compositions for Intranasal Delivery	U.S.A.	13/640,623	9,687,536
	Canada	2,993,242	
	EPO	13189570.8	
	China	201180027287.1	ZL 201180027287.1
	Korea	10-2012-7030060	

The patents and patent applications listed above are hereinafter referred to as "Applications", and the inventions disclosed in the "Applications" are hereinafter referred to as "Inventions".

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Assignee:

- Said Assignor does hereby sell, assign, transfer and convey unto said Assignee all the right, title and interest that The Chemo-Sero-Therapeutic Research Institute holds in and to said Inventions.
- Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty.
- The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its successors, assigns and other legal representatives.
- Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.
- This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Assignee.

**ASSIGNOR:**

**The Chemo-Sero-Therapeutic Research Institute**

Date: November 7, 2018

By: M. Kinoshita  
 Name: Motoharu KINOSHITA  
 Title: Director General

**RECEIVED AND AGREED TO BY ASSIGNEE:  
 KM Biologics Co., Ltd.**

Date: December 10, 2018

By: T. Nagasato  
 Name: Toshiaki NAGASATO  
 Title: Representative Director